Do inhaled corticosteroids decrease the risk of cardiovascular outcomes in patients with chronic obstructive pulmonary disease? DOI
David M. Mannino

Thorax, Год журнала: 2024, Номер unknown, С. thorax - 222606

Опубликована: Дек. 31, 2024

Язык: Английский

Development of Novel Fluticasone/Salmeterol/Tiotropium-Loaded Dry Powder Inhaler and Bioequivalence Assessment to Commercial Products in Rats DOI Creative Commons
Hyuk Jun Cho, Hyunji Lee, Duhyeong Hwang

и другие.

Pharmaceutics, Год журнала: 2025, Номер 17(1), С. 103 - 103

Опубликована: Янв. 14, 2025

Background/Objectives: Inhaler devices have been developed for the effective delivery of inhaled medications used in treatment pulmonary diseases. However, differing operating procedures across can lead to user errors and reduce efficacy, especially when patients use multiple simultaneously. To address this, we a novel dry powder inhaler (DPI), combining fluticasone propionate (FP), salmeterol xinafoate (SX), tiotropium bromide (TB) into single device designed bioequivalent compared existing commercial products an animal model. Methods: The micronized FP/SX/TB-loaded capsule was prepared by sieving, blending, filling capsules. Capsule suitability drugs investigated from comparison stability within various formulations that products. particle size adjusted using spiral air jet milling, ratio lactose hydrate carriers optimized comparing aerodynamic distribution (APSD) with investigate bioequivalence DPI products, dissolution profile FP/SX/TB particles pharmacokinetics rats were evaluated Results: Capsules hydroxypropyl methylcellulose (HPMC) without gelling agent showed superior deposition pattern influenced drugs, fine mass exhibited significant correlation amount carrier. Micronized gave similar APSD dose uniformity device. Furthermore, as evidenced no differences pharmacokinetic parameters following intratracheal administration rats. Conclusions: A triple-combination containing successfully developed, demonstrating comparable pharmacological performance Optimized HPMC achieved rat studies, suggesting its potential improved patient compliance therapeutic outcomes. This single-device offers promising alternative triple therapy

Язык: Английский

Процитировано

0

Do inhaled corticosteroids decrease the risk of cardiovascular outcomes in patients with chronic obstructive pulmonary disease? DOI
David M. Mannino

Thorax, Год журнала: 2024, Номер unknown, С. thorax - 222606

Опубликована: Дек. 31, 2024

Язык: Английский

Процитировано

0